Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: Summary report of the full submission to NICE, and beyond

Heart

Volumn 86, Issue 3, 2001, Pages 259-261

  Manoharan, G ^a   Adgey, A A J ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TIROFIBAN;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGINA, UNSTABLE; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME;

EID: 0034865594     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK)
2. Coronary plaque disruption
3. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
4. The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
5. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
6. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
8. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and Q-wave myocardial infarction
10. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
12. 3 blockade with percutaneous coronary intervention
13. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 Trial
14. Importance of antithrombin therapy in combination with abciximab and low-dose fibrinolytic therapy: Preliminary results of the GUSTO-4 pilot study
15. Combination low dose t-PA and eptifibatide for acute myocardial infarction - Final results of the INTRO-AMI study
16. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
17. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study
18. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL study, 30-day results
19. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 Trial
20. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
21. Coronary stenting and use of abciximab
22. Safe use of platelet GP IIb/IIIa inhibitors
23. Acute coronary syndromes: Drug treatments